ArticleCurrent oncology (Toronto, Ont.)2026
Tamoxifen Reduces Breast Cancer Recurrence in Women with DCIS Who Underwent Mastectomy.
Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reply to Venkataraman, J.; Mokbel, K. Reconsidering the Interpretation of "Recurrence-Free Survival" After Mastectomy for DCIS. Comment on "Sae-sim et al. Tamoxifen Reduces Breast Cancer Recurrence in Women with DCIS Who Underwent Mastectomy.Current oncology (Toronto, Ont.) · 2026Article
- Reconsidering the Interpretation of "Recurrence-Free Survival" After Mastectomy for DCIS. Comment on Sae-sim et al. Tamoxifen Reduces Breast Cancer Recurrence in Women with DCIS Who Underwent Mastectomy.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant tamoxifen reduces recurrence in patients with ER-positive DCIS treated with lumpectomy and radiation, but its benefit after mastectomy remains unclear.
methodsWe retrospectively analyzed 287 patients who underwent mastectomy for pure DCIS at Siriraj Hospital between 2008 and 2017. Recurrence risk factors were assessed using log-rank test, and survival probabilities were estimated with Kaplan-Meier analysis.
resultsOf 180 patients with hormone receptor (HR)-positive pure DCIS treated with mastectomy, 120 (66.7%) received tamoxifen, while the remaining 60 (33.3%) did not. The median follow-up was 8.07 years (0.05-13.8 years). Sixteen (8.9%) recurrences were identified, with 5 in the tamoxifen group and 11 in non-endocrine-therapy (ET) group. The 10-year recurrence-free survival (RFS) was 94.7% in the tamoxifen group compared with 77.9% in the non-ET group. Patients with HR-positive DCIS treated with tamoxifen following mastectomy had significantly less subsequent breast cancer (HR = 0.178;
conclusionsRecurrence of breast cancer after mastectomy for DCIS is rare; however, it carries a high mortality rate for those who relapse. Adjuvant tamoxifen after mastectomy demonstrated a significant reduction in the risk of recurrence in ER-positive DCIS. This study supports the decision to prescribe adjuvant ET in patients with DCIS who underwent mastectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.